Core Viewpoint - The company Shuoshi Biological (688399) reported a significant decline in performance for the first half of 2025, despite reaching a new high in stock price earlier in the year [1][2]. Financial Performance - The company achieved operating revenue of approximately 176 million yuan, a year-on-year decrease of 1.05% [2]. - The net profit attributable to shareholders was about 3.99 million yuan, down 86.35% compared to the previous year [2]. - The total profit for the period was approximately 7 million yuan, reflecting a decline of 78.37% [2]. - The net cash flow from operating activities was negative, amounting to -575.64 thousand yuan, a decrease of 100.77% [2]. - The company's net assets at the end of the reporting period were approximately 3.25 billion yuan, a slight increase of 0.13% from the previous year [2]. Business Overview - Shuoshi Biological focuses on the research, production, and sales of in vitro diagnostic reagents and related testing instruments, expanding into in vitro testing services [1]. - The company has over 700 products used in various fields, including infectious disease prevention, clinical testing, and population screening [1]. - The in vitro diagnostic reagent business accounted for 85.89% of total revenue in the first half of 2025, down from 90.25% in the same period last year [3]. Industry Context - The in vitro diagnostic industry is experiencing intense competition, with companies increasing R&D investments to develop more efficient and accurate diagnostic products [3]. - Despite existing barriers to entry, the industry's high profit margins and growth potential are attracting more capital, which may intensify competition [3]. R&D and Future Plans - R&D investment decreased by 13.11% year-on-year, amounting to approximately 40.64 million yuan, with the proportion of R&D spending relative to revenue dropping from 26.36% to 23.15% [4]. - The number of R&D personnel also declined from 144 to 128 [4]. - The company plans to distribute a cash dividend of 34 yuan per 10 shares, totaling approximately 285 million yuan [4]. - To support international development, the company intends to invest 3 million USD in establishing a subsidiary in Brazil [4].

据证券之星公开数据整理，近期硕世生物（688399）发布2025年中报。根据财报显示，硕世生物净利润 减86.35%。截至本报告期末，公司营业总收入1.76亿元，同比下降1.05%，归母净利润399.26万元，同 比下降86.35%。按单季度数据看，第二季度营业总收入8397.21万元，同比下降2.73%，第二季度归母净 利润-882.68万元，同比上升18.48%。 本次财报公布的各项数据指标表现不尽如人意。其中，毛利率62.44%，同比减8.35%，净利率2.27%， 同比减86.2%，销售费用、管理费用、财务费用总计9632.35万元，三费占营收比54.86%，同比增 8.66%，每股净资产38.81元，同比减33.76%，每股经营性现金流-0.01元，同比减100.54%，每股收益 0.05元，同比减85.29% 商业模式：公司业绩主要依靠营销驱动。需要仔细研究这类驱动力背后的实际情况。 | 基金筒称 | 基金代码 | 持有股数 | 持仓变动 | 数据来源 | | --- | --- | --- | --- | --- | | 鑫元专精特新混合A | 015071 | 12.00万股 | 增仓 | 2 ...

公司代码：688399 公司简称：硕世生物 第一节重要提示 1.1本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规 划，投资者应当到www.sse.com.cn网站仔细阅读半年度报告全文。 1.2重大风险提示 公司已在本报告中详细阐述公司在经营过程中可能面临的各种风险及应对措施，敬请查阅本报告第三 节"管理层讨论与分析"之"四、风险因素"。 1.3本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、完整 性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 1.4公司全体董事出席董事会会议。 1.5本半年度报告未经审计。 1.6董事会决议通过的本报告期利润分配预案或公积金转增股本预案 2025年8月7日，公司召开第三届董事会第十二次会议审议通过了《关于2025年半年度利润分配预案的议 案》，公司拟以实施权益分派股权登记日登记的总股本为基数，向全体股东每10股派发现金红利34.00 元（含税）。截至本公告披露日，公司总股本为83,871,721股，以此计算本次合计拟派发现金红利 285,163,851.40元（含税）。本次利润分 ...

Core Viewpoint - The company reported a decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [2] Financial Performance - The company achieved an operating revenue of 175,580,501.65 yuan in the first half of 2025, representing a year-on-year decrease of 1.05% [2] - The net profit attributable to shareholders was 3,992,614.61 yuan, which reflects a significant year-on-year decline of 86.35% [2]

Group 1 - The company, Shuoshi Biotechnology, announced the approval of multiple proposals during the tenth meeting of its third supervisory board, including the proposal for the 2025 semi-annual report and its summary [2]

Group 1 - The company, Shuoshi Biotechnology, announced that it will hold its first extraordinary general meeting of shareholders for 2025 on August 27, 2025 [1] - The agenda for the meeting includes the review of the proposal regarding the profit distribution plan for the first half of 2025 [1]

按申万行业统计，硕世生物所属的医药生物行业共有5家公司公布了2025半年度分配方案，派现金额最 多的是药明康德，派现金额为10.03亿元，其次是硕世生物、九洲药业，派现金额分别为2.85亿元、1.76 亿元。（数据宝） 2025半年度医药生物行业分红排名 | 代码 | 简称 | 每10股送转 | 每10股派现 | 派现金额（万 | 派现占净利润比例 | 股息率 | | --- | --- | --- | --- | --- | --- | --- | | | | （股） | （元） | 元） | （%） | （%） | | 603259 | 药明康 德 | 0.00 | 3.5 | 100308.38 | 11.72 | 0.58 | | 688399 | 硕世生 物 | 0.00 | 34 | 28516.39 | 7142.28 | 5.17 | | 603456 | 九洲药 业 | 0.00 | 2 | 17634.20 | 33.54 | 1.42 | | --- | --- | --- | --- | --- | --- | --- | | 000915 | 华特达 因 | 0.00 | 5 | 1 ...

Group 1: Company Announcements - Puyuan Precision plans to issue H-shares and list on the Hong Kong Stock Exchange [4] - Wanxing Technology intends to issue H-shares and list on the Hong Kong Stock Exchange [11] - Liou Co. plans to use no more than 3 billion yuan of its own funds for securities investment [13] - Guangdong Hongda's subsidiary intends to acquire 60% equity of Changzhilin for 1.02 billion yuan [12] Group 2: Financial Performance and Investments - GSK Gas plans to use 350 million yuan of raised funds for the Wuhan GSK Semiconductor Electronic Gas Station project, with a total investment of 503 million yuan [3] - Lianyungang's wholly-owned subsidiary plans to invest 548.8 million yuan in shipbuilding [2] - Hongjing Optoelectronics plans to invest 1.533 billion yuan in the construction of its R&D and manufacturing headquarters [9] Group 3: Regulatory Issues - Jihua Group is under investigation by the China Securities Regulatory Commission for suspected information disclosure violations [7] - *ST Gaohong may face forced delisting due to major violations related to fraudulent issuance of shares and false records in annual reports from 2015 to 2023 [8] Group 4: Sales Performance - Jingji Zhinnong reported sales of 3.51 billion yuan from selling 203,600 pigs in July, with a cumulative sales revenue of 2.243 billion yuan from January to July [8] - Zhengbang Technology reported sales of 7.41 billion yuan from selling 695,200 pigs in July, with a cumulative sales revenue of 4.818 billion yuan from January to July, showing significant year-on-year growth [10] Group 5: Share Transfers - Anzheng Fashion's shareholder plans to transfer 5.35% of the company's shares at a price of 6.78 yuan per share, totaling 141 million yuan [5] - Bidetech's actual controller and associates plan to transfer 29.9% of the company's shares to Dinglong Qishun for 897 million yuan [6]

Group 1: Investment Announcements - Panjiang Co. plans to increase investment by 55.8 million yuan in its wholly-owned subsidiary, New Energy Zhenning Co., for the construction of a wind power project with a total investment of 279 million yuan [1] - Lianyungang's wholly-owned subsidiary, Yunport Ferry Co., intends to invest 548.8 million yuan in building a passenger and vehicle ferry, having signed a construction contract with Huanghai Shipbuilding Co. [1] - Guanggang Gas plans to use 350 million yuan of raised funds for the Wuhan Guanggang Semiconductor Electronic Gas Station project, with a total planned investment of 503 million yuan [1] - Hongjing Optoelectronics intends to invest in a new R&D and manufacturing headquarters with a total investment of 1.533 billion yuan [6] Group 2: Share Transfers - Anzheng Fashion's shareholder plans to transfer 5.35% of the company's shares, totaling 20.8 million shares at a price of 6.78 yuan per share, amounting to 141 million yuan [2] - Bidetech's actual controllers plan to transfer 29.9% of the company's shares, totaling 56.1672 million shares at a price of 15.97 yuan per share, amounting to 897 million yuan [3] Group 3: Financial Performance - Jingji Zhino reported sales of 203,600 pigs in July, generating revenue of 351 million yuan, with a cumulative sales revenue of 2.243 billion yuan from January to July [6] - Zhengbang Technology reported sales of 695,200 pigs in July, with a revenue of 741 million yuan, showing a year-on-year increase of 91.38% and a cumulative revenue of 4.818 billion yuan from January to July [6] - Shuoshi Bio reported a 1.05% decrease in revenue to 176 million yuan for the first half of the year, with a net profit decline of 86.35% to 3.9926 million yuan [9] Group 4: Regulatory Issues - Jihua Group is under investigation by the China Securities Regulatory Commission for suspected information disclosure violations [4] - *ST Gaohong received a notice indicating potential major illegal delisting due to fraudulent issuance of shares and false records in annual reports from 2015 to 2023 [4] Group 5: Other Announcements - Wanjing Technology plans to issue H-shares and list on the Hong Kong Stock Exchange [7] - Guangdong Hongda's subsidiary intends to acquire 60% of Changzhilin for 1.02 billion yuan, enhancing its defense equipment business [7] - Lio Co. approved a plan to use up to 3 billion yuan of its own funds for securities investments [8]

Core Points - The company Shuoshi Bio (688399) reported a revenue of 176 million yuan for the first half of 2025, representing a year-on-year decrease of 1.05% [2] - The net profit attributable to the company was 3.99 million yuan, down 86.35% compared to the same period last year [2] Financial Performance - The decline in net profit is primarily attributed to the pressure on product prices due to the deep implementation of centralized procurement in the in vitro diagnostic industry across the country [2] - An adjustment in the value-added tax rate for self-produced testing reagents to 13% contributed to the decrease in gross margin [2] - There was a reduction in the reversal of impairment provisions for receivables and a decrease in government subsidies during the reporting period [2]